Effect of atorvastatin on chronic periodontitis: a randomized pilot study.

AIM: We studied the effect of atorvastatin (ATV) treatment on bone loss prevention in subjects with chronic periodontitis. MATERIAL AND METHODS: In this controlled double-blind study, 38 subjects with chronic periodontitis were randomized into two groups, paired by age to receive ATV (20 mg) or placebo daily for 3 months. Periodontal mechanical treatment was carried out in both groups at baseline. Clinical and radiographic parameters and bone turnover markers were assessed at baseline and at 3 months. RESULTS: Periodontal disease conditions improved in both groups. After comparing the figures of change, significant improvements were observed in cholesterol levels (Δ=-58.5 ± 37.6 versusΔ=5.4 ± 41.2 mg/dl, p<0.0002), low-density lipoprotein levels (Δ=-48.1 ± 31.7 versusΔ=1.9 ± 42.8 mg/dl, p<0.002), dental mobility (Δ=-0.17 ± 0.11 versusΔ=-0.06 ± 0.11%, p<0.04), and the distance from the crestal alveolar bone to the cemento-enamel junction (Δ=-0.75 ± 0.7 versusΔ=0.09 ± 0.4 mm, p<0.0006) in the ATV group. CONCLUSIONS: The results suggest that ATV might have beneficial effects on bone alveolar loss and tooth mobility in subjects with periodontal disease.

The relationship of estrogen receptor-alpha polymorphism with symptoms and other characteristics in post-menopausal women.

OBJECTIVES: To study the influence of the estrogen receptor-alpha (ER-alpha) genotypes (PvuII and XbaI polymorphisms) on symptoms and bone density. METHODS: We recruited 177 post-menopausal women to register hot flashes, vaginal dryness, depression, anxiety, sleep alterations, and serum hormones (FSH, LH, estrone, and estradiol). Bone mineral density (BMD) was measured with a radiographic method, correcting with an external reference. ER-alpha genotyping was carried out by PCR. RESULTS: Scores for vaginal dryness were lower for the xx (P = 0.003), and pp genotypes (P = 0.006). Hot flashes were lower for the Pp (P = 0.006) genotype. FSH circulating levels were lower for Xx genotype (P = 0.036). The factors associated with BMD were estrone (P > 0.000001), estradiol (P = 0.0035) and XbaI (P = 0.035). Vaginal dryness, was associated with PvuII and XbaI polymorphisms (P = 0.037 and P = 0.039). Depression was associated with log(estrone) (P = 0.011), schooling (negatively, P = 0.012), and marginally with BMI (P = 0.066). Sleep alterations correlated with log(estrone) (P = 0.014) and marginally with years since menopause (P = 0.046). Anxiety correlated with schooling (negatively, P = 0.006) and age (p = 0.015), and hot flashes with schooling (negatively, P = 0.014). BMD was associated with log(estrone) (p < 0.000001), estradiol (negatively, P = 0.0036), and marginally with XbaI (P = 0.036). CONCLUSIONS: In post-menopausal women, the ER-alpha polymorphism was associated with vaginal dryness, and hot flashes but not with other physical or emotional symptoms. Extraglandular estrogen production, and diverse molecular factors related to estrogen action may play an important role in this process.